Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Other Financing Activities

Financing cash flows not reported separately.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $0.

Context

  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$0-100.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's LTM Mar 2026 other financing activities of $0 is the 5th largest of the 6 companies compared; the peer median is $373K.
  • Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +926.3%.
BCAX Competitors Peer median
Other Financing Activities for BCAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CBIOCrescent Biopharma, Inc.LTM Mar 2026$145.55M +19251.3%—1224.9%
MGNXMacroGenics, Inc.LTM Mar 2026$139.12M +52398.9%+394.4%88.6%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$9.34M +926.3%+28.9%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$373K +108.4%——
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$0 -100.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026$0 +100.0%——
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $373K+926.3%+211.7%656.7%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.85M)(51.99M)(68M)(137.95M)
Depreciation & Amortization10K19K56K406K
Deferred Income Tax0000
Stock-Based Compensation810K1.9M7.4M15.01M
Change in Working Capital4.95M(9.62M)(14.13M)14.81M
Accounts Receivables0000
Inventory0000
Accounts Payables002.64M0
Other Working Capital4.95M(9.62M)(16.77M)14.81M
Other Non-Cash Items810K14.06M(77K)895K
Operating Cash Flow(32.08M)(45.63M)(74.75M)(106.83M)
Capital Expenditures(192K)(586K)(71K)(280K)
Acquisitions (Net)0000
Purchases of Investments000(318.17M)
Sales of Investments0000
Other Investing Activities0062K0
Investing Cash Flow(192K)(586K)(9K)(318.45M)
Debt Repayment0000
Common Stock Issued00332.43M32.26M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities160K149K1.6M0
Financing Cash Flow31.7M272.5M334.03M32.26M
Effect of Forex Changes0000
Net Change in Cash(573K)226.28M259.27M(393.03M)
Free Cash Flow(32.27M)(46.21M)(74.82M)(107.11M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.